Current evidence in channelopathy gene therapy

12 April 2026 (11:45 - 12:00)

Organised by:

Slides

Sign in for access options

About the speaker

Professor Katja Odening

Bern University Hospital, Inselspital, Bern (Switzerland)

3 More presentations in this session

Presentation thumbnail

Polygenic risk score: is there a clinical role in Brugada and long QT syndromes?

Professor E. Behr (London, GB)

Presentation thumbnail

Translating basic science into novel pharmacological strategies in channelopathies

Associate Professor C. Remme (Amsterdam, NL)

Presentation thumbnail

Gene therapy for channelopathies: clinical trials on the horizon and the patient selection challenge

Doctor D. Abrams (Boston, US)

Access the full session

Session thumbnail

Novel diagnostic and therapeutic approaches in channelopathies

The Event

Event poster

EHRA 2026

12 April 2026 11:45 CET

You may be interested in

Congress Presentation

Study of the cardiac sodium channel in a mouse model of Scn5a haploinsufficiency towards a novel approach of therapy

13 April 2024

Webinar

Interpretation and actionability of genetic variants in cardiomyopathies

7 March 2023

Congress Presentation

ASE: Young Investigator Awardee presentation: "Cavitation-facilitated augmentation of myocyte gene delivery with adeno-associated Vector-9: a bioengineering strategy to address clinical gaps in cardiac gene therapy"

11 December 2025

Congress Presentation

Therapeutic effect of selective serotonin reuptake inhibitors to gain-of-function KCND3 variant identified in a patient with early repolarization and refractory epilepsy.

1 September 2025

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources